---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-23-000028"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:22:20.169809+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q2 revenue up 47% to $41.5M; raises FY 2023 guidance to $150-160M

## Summary
- Q2 net revenue $41.5M (+47% YoY); net loss narrowed to $11.5M ($0.08 loss per share) from $35.5M ($0.25).
- Raised FY2023 LUPKYNIS revenue guidance to $150-160M; cited strong commercial execution.
- Patients on therapy reached 1,911 (+50% YoY); patient start forms +10% YoY to 451 in Q2.
- Gross margin 96%; cash and short-term investments $350.7M as of June 30, 2023.
- Initiated strategic review with J.P. Morgan as financial advisor.

## SEC filing metadata
- accession: 0001600620-23-000028
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000028/0001600620-23-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000028/auph-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-23-000028
- JSON: https://secwatch.observer/filing/0001600620-23-000028.json
- Plain text: https://secwatch.observer/filing/0001600620-23-000028.txt

## Key facts
- Earnings Releases
  Aurinia Pharmaceuticals Inc. reported three and six months ended June 30, 2023 results: revenue $41.5 million. Guidance raised.
  - Period: three and six months ended June 30, 2023
  - Revenue: $41.5 million
  - Guidance: raised
  - Result: reported results
  source text: Total net revenue was $41.5 million for the three months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000028/0001600620-23-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.